

# FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

|                                                                 |                                                   |                                                                                                               |
|-----------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| 1. Name and Address of Reporting Person *                       | 2. Issuer Name and Ticker or Trading Symbol       | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)                                    |
| <b>Konidaris Tasos</b>                                          | <b>Amneal Pharmaceuticals, Inc. [ AMRX ]</b>      | <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner                                          |
| (Last) (First) (Middle)                                         | 3. Date of Earliest Transaction (MM/DD/YYYY)      | <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) |
| <b>C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD</b> | <b>8/13/2025</b>                                  | <b>Executive Vice President &amp; CFO</b>                                                                     |
| (Street)                                                        | 4. If Amendment, Date Original Filed (MM/DD/YYYY) | 6. Individual or Joint/Group Filing (Check Applicable Line)                                                   |
| <b>BRIDGEWATER, NJ 08807</b>                                    |                                                   | <input checked="" type="checkbox"/> Form filed by One Reporting Person                                        |
| (City) (State) (Zip)                                            |                                                   | <input type="checkbox"/> Form filed by More than One Reporting Person                                         |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security<br>(Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code<br>(Instr. 8) |   | 4. Securities Acquired (A) or Disposed of (D)<br>(Instr. 3, 4 and 5) |            |            | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership<br>(Instr. 4) |
|------------------------------------|----------------|-----------------------------------|------------------------------|---|----------------------------------------------------------------------|------------|------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                                    |                |                                   | Code                         | V | Amount                                                               | (A) or (D) | Price      |                                                                                                  |                                                          |                                                          |
| Class A Common Stock               | 8/13/2025      |                                   | S                            |   | 161,365                                                              | D          | \$9.22 (1) | 460,517                                                                                          | D                                                        |                                                          |
| Class A Common Stock               | 8/14/2025      |                                   | S                            |   | 119,206                                                              | D          | \$9.3 (2)  | 341,311                                                                                          | D                                                        |                                                          |
| Class A Common Stock               | 8/15/2025      |                                   | S                            |   | 219,159                                                              | D          | \$9.43 (3) | 122,152                                                                                          | D                                                        |                                                          |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivate Security<br>(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code<br>(Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)<br>(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date |                 | 7. Title and Amount of Securities Underlying Derivative Security<br>(Instr. 3 and 4) |                            | 8. Price of Derivative Security<br>(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)<br>(Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership<br>(Instr. 4) |
|---------------------------------------------|--------------------------------------------------------|----------------|-----------------------------------|------------------------------|---|-------------------------------------------------------------------------------------------|-----------------------------------------|-----------------|--------------------------------------------------------------------------------------|----------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------|
|                                             |                                                        |                |                                   | Code                         | V |                                                                                           | Date Exercisable                        | Expiration Date | Title                                                                                | Amount or Number of Shares |                                               |                                                                                                       |                                                                                  |                                                           |

#### Explanation of Responses:

- (1) The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.12 to \$9.40 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
- (2) The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.25 to \$9.34 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.
- (3) The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.40 to \$9.47 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

#### Reporting Owners

| Reporting Owner Name / Address                                                                     | Relationships |           |                                           |       |
|----------------------------------------------------------------------------------------------------|---------------|-----------|-------------------------------------------|-------|
|                                                                                                    | Director      | 10% Owner | Officer                                   | Other |
| <b>Konidaris Tasos</b><br><b>C/O AMNEAL PHARMACEUTICALS, INC.</b><br><b>400 CROSSING BOULEVARD</b> |               |           | <b>Executive Vice President &amp; CFO</b> |       |

|                       |  |  |  |  |
|-----------------------|--|--|--|--|
| BRIDGEWATER, NJ 08807 |  |  |  |  |
|-----------------------|--|--|--|--|

**Signatures**

**/s/ Denis Butkovic, Attorney-in-Fact**

**8/15/2025**

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.